Evidence map›Paper›PMID 22066016›Full record

ArticlePloS one2011

Spleen-resident CD4+ and CD4- CD8α- dendritic cell subsets differ in their ability to prime invariant natural killer T lymphocytes.

Emilie Bialecki, Elodie Macho Fernandez, Stoyan Ivanov, Christophe Paget, Josette Fontaine, Fabien Rodriguez, Luc Lebeau, Christophe Ehret, Benoit Frisch, François Trottein and 1 more

Abstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Plasmacytoid dendritic cells in the eye.Progress in retinal and eye research · 2021
    Review
  6. Review
  7. Article
  8. LangerinFrontiers in immunology · 2019
    Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Emilie BialeckiCenter for Infection and Immunity of Lille, Institut Pasteur de Lille, Lille, France.
Elodie Macho Fernandez
Stoyan Ivanov
Christophe Paget
Josette Fontaine
Fabien Rodriguez
Luc Lebeau
Christophe Ehret
Benoit Frisch
François Trottein
Christelle Faveeuw

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One important function of conventional dendritic cells (cDC) is their high capacity to capture, process and present Ag to T lymphocytes. Mouse splenic cDC subtypes, including CD8α(+) and CD8α(-) cDC, are not identical in their Ag presenting and T cell priming functions. Surprisingly, few studies have reported functional differences between CD4(-) and CD4(+) CD8α(-) cDC subsets. We show that, when loaded in vitro with OVA peptide or whole protein, and in steady-state conditions, splenic CD4(-) and CD4(+) cDC are equivalent in their capacity to prime and direct CD4(+) and CD8(+) T cell differentiation. In contrast, in response to α-galactosylceramide (α-GalCer), CD4(-) and CD4(+) cDC differentially activate invariant Natural Killer T (iNKT) cells, a population of lipid-reactive non-conventional T lymphocytes. Both cDC subsets equally take up α-GalCer in vitro and in vivo to stimulate the iNKT hybridoma DN32.D3, the activation of which depends solely on TCR triggering. On the other hand, and relative to their CD4(+) counterparts, CD4(-) cDC more efficiently stimulate primary iNKT cells, a phenomenon likely due to differential production of co-factors (including IL-12) by cDC. Our data reveal a novel functional difference between splenic CD4(+) and CD4(-) cDC subsets that may be important in immune responses.

Indexed as

AnimalsCD4-Positive T-LymphocytesCD8 AntigensCross-PrimingDendritic CellsGalactosylceramidesKiller Cells, NaturalLymphocyte SubsetsMaleMiceMice, Inbred C57BLSpleenalpha-galactosylceramideCD8alpha antigenCD8 AntigensGalactosylceramides

Identifiers

PMID22066016
PMCPMC3204990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.